Skip to main content
SpringerLink
Log in

Recommendation of the scientific societies on the treatment of anaemia in cancer patients

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

At present, anaemia in the patients with cancer remains a problem of the first magnitude and of increasing interest due to the high incidence, the major knowledge of its physiopathology, the negative impact on the quality of life of the patient, the influence on the evolution of the disease and its treatments and, finally to the progressive development of new alternatives of treatment, especially the erythropoietic agents. For all this, it becomes necessary to consider the treatment of the anemia of the patients with cancer as a basic part of their support treatment. The erythropoietic agents have demonstrated in the last years that constitute a therapeutic alternative to obtain an increase of the levels of hemoglobin in the patients with anticancer treatments, considering specially that the correction of the anemia not only represents the improvement of an analytical value but also has a significant impact on the quality of life of the patients and diminishes the transfusion requirements. Erythropoietic proteins available for the treatment of the anemia of the patients with cancer are Epoetin-alfa, Epoetin-beta and Darbepoetin-alfa. The existence of different drugs, different doses and intervals of administration, clinical different situations and heterogeneous studies, made necessary the development of documents of consensus and guides of clinical recommendations which provide information on the scientific evidence that supports the use of these agents in medical care. This paper summarizes the main recommendations from panels of experts and scientific societies published so far.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ludwig H, Van Belle S, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306

    Article  PubMed  Google Scholar 

  2. Moreno-Nogueira JA, Bernabé R, Pineda MD, Sabino A (2005) Eritropoyesis y Anemia. In: Gascon P (ed.) Anemia y Cáncer. Ed You & Us, Madrid, pp 1–15

    Google Scholar 

  3. Ray-Coquard I, Le Cesne A, Rubio MT et al (1999) Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 17:2840–2846

    PubMed  CAS  Google Scholar 

  4. Caro J, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer. A systematic, quantitative review. Cancer 91:2214–2221

    Article  PubMed  CAS  Google Scholar 

  5. González-Barón M, Camps C, Gascón P et al (eds) (2005) Anemia y Cancer. Ed Panamericana, Madrid, pp 15–22

    Google Scholar 

  6. Crawford J, Cella D, Cleeland C et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888–895

    Article  PubMed  CAS  Google Scholar 

  7. Glaspy J, Degos L, Dicato M, Demetri GD (2002) Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum-and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 7:126–135

    Article  PubMed  CAS  Google Scholar 

  8. Littlewood TJ, Bajetta E, Nortier JWR et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874

    PubMed  CAS  Google Scholar 

  9. Quirt I, Robeson C, Lau CY et al (2001) Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol 19:4126–4134

    PubMed  CAS  Google Scholar 

  10. Vansteenkiste J, Pirker R, Massuti B et al (2002) Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211–1220

    PubMed  CAS  Google Scholar 

  11. Abels RI, Larholt KM, Krantz KD, Bryant EC (1996) Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1:140–150

    PubMed  CAS  Google Scholar 

  12. Seidenfeld J, Piper M, Flamm C et al (2001) Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 93:1204–1214

    Article  PubMed  CAS  Google Scholar 

  13. Rodríguez CA (2006) Impacto del intervalo de dosificación en el tratamiento de la anemia en el enfermo con cancer. Rev Cancer 20[Suppl 1]:66–70

    Google Scholar 

  14. Gabrilove J, Cleeland CS, Livingston RB et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875–2882

    PubMed  CAS  Google Scholar 

  15. Chang J, Couture F, Young S et al (2005) Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 23:2597–2605

    Article  PubMed  CAS  Google Scholar 

  16. Jones M, Schenkel B, Just J, Fallowfield L (2004) Epoetin alfa improves quality of life in patients with cancer. Cancer 101:1720–1732

    Article  PubMed  CAS  Google Scholar 

  17. Crawford J, Cella C, Cleeland CS et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888–895

    Article  PubMed  CAS  Google Scholar 

  18. Henke M, Laszig R, Rube C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260

    Article  PubMed  CAS  Google Scholar 

  19. Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960–5972

    Article  PubMed  CAS  Google Scholar 

  20. Bohlius J, Wilson J, Seidenfeld J et al (2006) Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708–714

    Article  PubMed  CAS  Google Scholar 

  21. Freemantle N, Yao B, Calvert M, Lillie T (2005) Impact of darbepoetin alfa on transfusion, hemoglobin response, and survival in cancer patients with chemotherapy-induced anemia: results of a meta-analysis of randomized, placebo-controlled trials. Blood 106:Abstr 3116

  22. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083–4107

    Article  PubMed  CAS  Google Scholar 

  23. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100:2303–2320

    Article  PubMed  CAS  Google Scholar 

  24. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14:671–679

    Google Scholar 

  25. Bokemeyer C, Aapro MS, Courdi A et al (2004) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 40:2201–2216

    Article  PubMed  CAS  Google Scholar 

  26. Bokemeyer C, Aapro MS, Courdi A et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258–270

    Article  PubMed  CAS  Google Scholar 

  27. (2007) NCCN Clinical Practice Guidelines in Oncology. Cancer and Treatment-Related Anemia. V.2.2007. Available at http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf

  28. Available at: http://www.fda.gov/medwatch/safety/2007/Aranesp_DHCP_012707.htm

  29. Wright JR, Ung YC, Julian JA et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027–1032

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Universitario de Salamanca, Paseo San Vicente, 58-182, ES-37007, Salamanca, Spain

    C. A. Rodríguez Sánchez

Authors
  1. C. A. Rodríguez Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. A. Rodríguez Sánchez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodríguez Sánchez, C.A. Recommendation of the scientific societies on the treatment of anaemia in cancer patients. Clin Transl Oncol 9, 582–589 (2007). https://doi.org/10.1007/s12094-007-0107-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0107-3

Key words

Search

Navigation